Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAIN: WGA-800CW for Detection of Esophageal Dysplasia in Barrett's Esophagus
NCT07643727Phase 1Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WGA-800CW in Barrett's esophagus, esophageal dysplasia and esophageal adenocarcinoma (EAC), sponsored by University Medical Center Groningen. Primary endpoints: Optimal dose of WGA-800CW and Feasibility for detection of dysplastic esophageal lesions. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
WGA-800CW
03
Conditions
Barrett's esophagusesophageal dysplasiaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07643727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643727.